Ruthenium Dioxide Nanoparticles Treat Alzheimer's Disease by Inhibiting Oxidative Stress and Alleviating Neuroinflammation

Ran Tang,Xiaoyu Yuan,Zhi Jia,Fang Yang,Gang Ye,Jie Liu
DOI: https://doi.org/10.1021/acsanm.3c01650
IF: 6.14
2023-01-01
ACS Applied Nano Materials
Abstract:Oxidative stress and neuroinflammation have receivedwidespreadattention as mechanisms of Alzheimer's disease (AD) pathogenesis.Oxidative stress, serving as a "bridge" between varioushypotheses, has been shown to interact with several pathological features(neuroinflammation, & beta;-amyloid deposition) and forms a viciouscircle that accelerates the progression of AD. Herein, we report rutheniumdioxide nanoparticles (RuO2 NPs) with diverse enzymaticactivities and reactive oxygen species (ROS) elimination functions.The poly(vinylpyrrolidone) (PVP) on the surface of RuO2 NPs was used to link with borneol (Bor) to help it pass throughthe blood-brain barrier (BBB). In vitro and in vivo experiment results have shown that RuO2@Bor possesses good biocompatibility and multiple antioxidant-likeenzymatic activities, which can scavenge ROS, protect neurons fromoxidative damage, and repair impaired mitochondrial function. In addition,RuO2@Bor could also regulate microglia polarization (frompro-inflammatory M1-phenotype microglial to anti-inflammatory M2 phenotypemicroglial) and inhibit the release of pro-inflammatory factors (TNF-& alpha;,IL-6) to effectively relieve neuroinflammation. In vivo experiments further demonstrated that RuO2@Bor not onlyeffectively improved the cognitive and memory abilities of AD modelmice but also acted as an effective neuroprotective agent. The resultssuggest that RuO2@Bor would be a potential drug for themultitarget treatment of AD.
What problem does this paper attempt to address?